XML 87 R20.htm IDEA: XBRL DOCUMENT
v3.20.1

Shareholders' Equity | 12 Months Ended
--- | ---
Dec. 31, 2019
Stockholders' Equity Note [Abstract] |
Shareholders' Equity | Note 12 - Shareholders' Equity Capital and reserves On May 2, 2019, the Company's Board of Directors authorized and began implementation of a one-year share repurchase plan to repurchase up to $15 million of the Company's ordinary shares. Repurchases may be made in the open market and will be in accordance with applicable securities laws and regulations. The timing and amount of each repurchase transaction may depend on a variety of factors. The share repurchase plan does not obligate the Company to acquire any specific number of ordinary shares and may be suspended or terminated at any time at management’s discretion. Share based compensation
| A. | On October 21, 2013 the Board resolved to adopt the Global Share Incentive Plan (2013) (the "2013 Plan") and to reserve up to 500,000 ordinary shares for issuance under the 2013 Plan to employees, directors, officers and consultants of the Company or of any subsidiary or affiliate of the Company. In January 2018, our Board approved the increase of the number of ordinary shares reserved for issuance under the 2013 Plan by 600,000 additional ordinary shares. Grants under the 2013 Plan, whether as options, restricted stock units, restricted stock or other equity based awards, including their terms, are subject to the Board of Directors' approval. Grants to directors and certain other officers are generally subject to the approvals of the Compensation Committee as well as Board of Directors, and grants to directors or a CEO (and under certain circumstances certain other officers) will also have to be approved by the Shareholders.
| B. | Options or RSUs granted to Israeli residents may be granted under Section 102 of the Israeli Income Tax Ordinance pursuant to which the awards of options, or the ordinary shares issued upon their exercise, must be deposited with a trustee for at least two years following the date of grant. Under Section 102, any tax payable by an employee from the grant or exercise of the awards is deferred until the transfer of the awards or ordinary shares by the trustee to the employee or upon the sale of the awards or ordinary shares.
Capital gains on awards granted under the plans are subjected to tax of 25% to be paid by the employee, and the Company is not entitled to a tax deduction. Gains which are not capital gains on awards under the plans are subjected to regular tax rates on individuals, and the Company is entitled to a tax deduction for such gains.
| C. | During 2014, 2015 and 2017, the Company granted 74,000, 8,000 and 78,000 RSUs respectively to certain of its directors, employees and consultants under the 2013 Plan. In relation to those grants:
| 1. | The vesting period of the RSUs ranges between 2 to 3 years from the date of grant.
| 2. | The fair value of RSUs is estimated based on the market value of the Company’s stock on the date of grant, less an estimate of dividends that will not accrue to RSUs holders prior to vesting.
| 3. | The Company recognizes compensation expenses on these RSUs based on estimated grant date fair value, with the following assumptions:
|  | 2014 |  |  | 2015 |  |  | 2017 |
Expected dividend yield |  |  | 2.06 | % |  |  | 3.22 | % |  |  | 2.68 | %
Termination rate |  |  | 4.35 | % |  |  | 0 | % |  |  | 1.74 | %
| D. | On July 28, 2015, the Company granted, in the aggregate, 89,907 options to certain of its directors and employees under the 2013 Plan. In relation to this grant:
| 1. | The exercise price for the options (per ordinary share) was US$ 26.91 and the Option expiration date was the earlier to occur of: (a) July 28, 2023; and (b) the closing price of the shares falling below US$ 13.46 at any time after the date of grant. The options vest and become exercisable on the second anniversary of the date of grant.
| 2. | The Company recognizes compensation expenses on these options based on estimated grant date fair value using the Binomial option-pricing model with the following assumptions:
Average Risk-free interest rate (a) |  |  | 2.08 | %
Expected dividend yield |  |  | 2.09 | %
Average expected volatility (b) |  |  | 53.01 | %
Termination rate |  |  | 9 | %
Suboptimal factor (c) |  |  | 3.4 |
(a) | Risk-free interest rate represents risk free US$ zero-coupon US Government Bonds at time of grant.
(b) | Expected average volatility represents a weighted average standard deviation rate for the price of the Company’s ordinary shares on the NASDAQ National Market.
(c) | Suboptimal factor represents the multiple of the increase in the market share price on the day of grant of the option which, should it come to pass, will lead to exercise of the option by the employee. It is the average suboptimal factor of the Company and similar companies.
| E. | On June 8, 2016, the Company granted, in the aggregate, 93,660 options to certain of its directors and employees under the 2013 Plan. In relation to this grant:
| 1. | The exercise price for the options (per ordinary share) was US$ 28.38 and the Option expiration date was the earlier to occur of: (a) June 8, 2024; and (b) the closing price of the shares falling below US$ 14.19 at any time after the date of grant. The options vest and become exercisable on the second anniversary of the date of grant.
| 2. | The Company recognizes compensation expenses on these options based on estimated grant date fair value using the Binomial option-pricing model with the following assumptions:
Average Risk-free interest rate (a) |  |  | 1.58 | %
Expected dividend yield |  |  | 2.42 | %
Average expected volatility (b) |  |  | 47.90 | %
Termination rate |  |  | 9 | %
Suboptimal factor (c) |  |  | 3.32 |
(a) | Risk-free interest rate represents risk free US$ zero-coupon US Government Bonds at time of grant.
(b) | Expected average volatility represents a weighted average standard deviation rate for the price of the Company’s ordinary shares on the NASDAQ National Market.
(c) | Suboptimal factor represents the multiple of the increase in the market share price on the day of grant of the option which, should it come to pass, will lead to exercise of the option by the employee. It is the average suboptimal factor of the Company and similar companies.
| F. | On January 30, 2017, the Company granted, in the aggregate, 119,925 options to certain of its directors and employees under the 2013 Plan. In relation to this grant:
| 1. | The exercise price for the options (per ordinary share) was US$ 39.62 and the Option expiration date was the earlier to occur of: (a) January 30, 2025; and (b) the closing price of the shares falling below US$ 19.81 at any time after the date of grant. The options vest and become exercisable on the second anniversary of the date of grant.
| 2. | The Company recognizes compensation expenses on these options based on estimated grant date fair value using the Binomial option-pricing model with the following assumptions:
Average Risk-free interest rate (a) |  |  | 2.35 | %
Expected dividend yield |  |  | 2.42 | %
Average expected volatility (b) |  |  | 43.71 | %
Termination rate |  |  | 9 | %
Suboptimal factor (c) |  |  | 3.28 |
(a) | Risk-free interest rate represents risk free US$ zero-coupon US Government Bonds at time of grant.
(b) | Expected average volatility represents a weighted average standard deviation rate for the price of the Company’s ordinary shares on the NASDAQ National Market.
(c) | Suboptimal factor represents the multiple of the increase in the market share price on the day of grant of the option which, should it come to pass, will lead to exercise of the option by the employee. It is the average suboptimal factor of the Company and similar companies.
| G. | On April 30, 2018, the Company granted, in the aggregate, 137,010 options to certain of its directors and employees under the 2013 Plan. In relation to this grant:
| 1. | The exercise price for the options (per ordinary share) was US$ 36.11 and the Option expiration date was the earlier to occur of: (a) April 30, 2026; and (b) the closing price of the shares falling below US$ 18.06 at any time after the date of grant. The options vest and become exercisable on the second anniversary of the date of grant.
| 2. | The Company recognizes compensation expenses on these options based on estimated grant date fair value using the Binomial option-pricing model with the following assumptions:
Average Risk-free interest rate (a) |  |  | 2.92 | %
Expected dividend yield |  |  | 0.0 | %
Average expected volatility (b) |  |  | 45.13 | %
Termination rate |  |  | 9 | %
Suboptimal factor (c) |  |  | 3.2 |
(a) | Risk-free interest rate represents risk free US$ zero-coupon US Government Bonds at time of grant.
(b) | Expected average volatility represents a weighted average standard deviation rate for the price of the Company’s ordinary shares on the NASDAQ National Market.
(c) | Suboptimal factor represents the multiple of the increase in the market share price on the day of grant of the option which, should it come to pass, will lead to exercise of the option by the employee. It is the average suboptimal factor of the Company and similar companies.
| H. | On January 31, 2019, the Company granted, in the aggregate, 141,928 options to certain of its directors and employees under the 2013 Plan. In relation to this grant:
| 1. | The exercise price for the options (per ordinary share) was US$ 33.83 and the Option expiration date was the earlier to occur of: (a) January 31, 2027; and (b) the closing price of the shares falling below US$ 16.92 at any time after the date of grant. The options vest and become exercisable on the second anniversary of the date of grant.
| 2. | The Company recognizes compensation expenses on these options based on estimated grant date fair value using the Binomial option-pricing model with the following assumptions:
Average Risk-free interest rate (a) |  |  | 2.55 | %
Expected dividend yield |  |  | 0.0 | %
Average expected volatility (b) |  |  | 44.62 | %
Termination rate |  |  | 9 | %
Suboptimal factor (c) |  |  | 3.18 |
(a) | Risk-free interest rate represents risk free US$ zero-coupon US Government Bonds at time of grant.
(b) | Expected average volatility represents a weighted average standard deviation rate for the price of the Company’s ordinary shares on the NASDAQ National Market.
(c) | Suboptimal factor represents the multiple of the increase in the market share price on the day of grant of the option which, should it come to pass, will lead to exercise of the option by the employee. It is the average suboptimal factor of the Company and similar companies.
| I. | The following table summarizes information regarding stock options as at December 31, 2019:
|  |  | Options outstanding |  |  | Options exercisable |
|  |  |  |  |  | Weighted average |  |  |  |  |  | Weighted average |
|  |  |  |  |  | remaining |  |  |  |  |  | remaining |
Exercise price |  |  | Number |  |  | contractual life |  |  | Number |  |  | contractual life |
US$ |  |  | of options |  |  | (in years) |  |  | of options |  |  | (in years) |
15.28 |  |  |  | 6,575 |  |  |  | 0.7 |  |  |  | 6,575 |  |  |  | 0.7 |
26.91 |  |  |  | 19,332 |  |  |  | 3.6 |  |  |  | 19,332 |  |  |  | 3.6 |
33.27 |  |  |  | 19,706 |  |  |  | 6.3 |  |  |  | 19,706 |  |  |  | 6.3 |
28.38 |  |  |  | 72,198 |  |  |  | 4.4 |  |  |  | 72,198 |  |  |  | 4.4 |
39.62 |  |  |  | 101,838 |  |  |  | 5.1 |  |  |  | 101,838 |  |  |  | 5.1 |
36.11 |  |  |  | 116,257 |  |  |  | 6.3 |  |  |  | - |  |  |  | - |
33.83 |  |  |  | 129,341 |  |  |  | 7.1 |  |  |  | - |  |  |  | - |
|  |  |  | 465,247 |  |  |  |  |  |  |  | 219,649 |  |  |  |  |
The aggregate intrinsic value of options outstanding as of December 31, 2018 and 2019 is US$ 835 thousand and US$ 593 thousand, respectively. The aggregate intrinsic value of options exercisable as of December 31, 2018 and 2019 is US$ 835 thousand and US$ 593 thousand, respectively. The total intrinsic value of options exercised during the year ended December 31, 2018 and 2019, is US$ 67 thousand and US$ 28 thousand, respectively.
| J. | The stock option activity under the abovementioned plans is as follows:
|  |  |  |  |  |  |  | Weighted |
|  |  |  |  | Weighted |  |  | average |
|  | Number |  |  | average |  |  | grant date |
|  | of options |  |  | exercise price |  |  | fair value |
|  |  |  |  | US$ |  |  | US$ |
Balance at January 1, 2017 |  |  | 266,005 |  |  |  |  |  |  |
Granted |  |  | 119,925 |  |  |  | 39.62 |  |  |  | 11.89 |
Exercised |  |  | (124,918 | ) |  |  | 21.46 |  |  |  | 8.46 |
Forfeited |  |  | (11,101 | ) |  |  | 33.18 |  |  |  | 10.87 |
Balance at December 31, 2017 |  |  | 249,911 |  |  |  |  |  |  |  |  |
Granted |  |  | 137,010 |  |  |  | 36.11 |  |  |  | 14.71 |
Exercised |  |  | (9,674 | ) |  |  | 28.02 |  |  |  | 9.94 |
Forfeited |  |  | (11,752 | ) |  |  | 36.73 |  |  |  | 13.05 |
Balance at December 31, 2018 |  |  | 365,495 |  |  |  |  |  |  |  |  |
Granted |  |  | 141,928 |  |  |  | 33.83 |  |  |  | 13.35 |
Exercised |  |  | (5,500 | ) |  |  | 28.09 |  |  |  | 10.03 |
Forfeited |  |  | (36,676 | ) |  |  | 35.88 |  |  |  | 13.50 |
Balance at December 31, 2019 |  |  | 465,247 |  |  |  |  |  |  |  |  |
Exercisable at December 31, 2019 |  |  | 219,649 |  |  |  |  |  |  |  |  |
| K. | The Restricted Share Units activity under the abovementioned plans is as follows:
|  |  |  |  | Weighted |
|  | Number of |  |  | average |
|  | Restricted |  |  | grant date |
|  | Share Units |  |  | fair value |
|  |  |  |  | US$ |
Balance at January 1, 2017 |  |  | 43,000 |  |  |  |
Granted |  |  | 78,000 |  |  |  | 34.90 |
Vested |  |  | (43,000 | ) |  |  | 42.52 |
Balance at December 31, 2017 and December 31, 2018 |  |  | 78,000 |  |  |  |  |
Vested |  |  | (39,000 | ) |  |  | 35.36 |
Balance at December 31, 2019 |  |  | 39,000 |  |  |  |  |
The aggregate intrinsic value of RSUs outstanding as of December 31, 2018 and December 31, 2019 is US$ 2,725 thousand and US$ 1,297 thousand, respectively.
| L. | During 2017, 2018 and 2019, the Company recorded share-based compensation expenses. The following summarizes the allocation of the stock-based compensation expenses:
|  | Year ended December 31 |
|  | 2017 |  |  | 2018 |  |  | 2019 |
|  | US$ thousands |
Cost of sales |  |  | 320 |  |  |  | 372 |  |  |  | 437 |
Research and development costs |  |  | 832 |  |  |  | 953 |  |  |  | 900 |
Selling and marketing expenses |  |  | 537 |  |  |  | 569 |  |  |  | 493 |
General and administrative expenses |  |  | 736 |  |  |  | 530 |  |  |  | 525 |
|  |  | 2,425 |  |  |  | 2,424 |  |  |  | 2,355 |
As of December 31, 2019, there were US$ 1,313 thousand of unrecognized compensation costs related to outstanding stock options and RSUs to be recognized over a weighted average period of 0.88 years.

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration